Yale Cancer Center

BostonGene and SWOG Cancer Research Network launched the PRISM study, a randomized Phase II trial evaluating biomarker-directed therapy for extensive stage small cell lung cancer patients.

The UNC Lineberger Comprehensive Cancer Center received $28 million from ARPA-H to develop EVOLVE, an innovative clinical trial that adapts metastatic breast cancer treatment in real-time based on tumor changes.

A machine learning-based approach integrating tumor and circulating biomarkers demonstrated superior predictive capability compared to individual biomarkers alone for patients with advanced renal cell carcinoma treated with nivolumab plus cabozantinib.

ProteinQure raised $11 million in Series A funding led by Heron Rock Fund to advance PQ203, a first-in-class AI-designed peptide-drug conjugate targeting triple-negative breast cancer.

Recent clinical trials evaluating immunotherapy agents in myelodysplastic syndromes (MDS) have shown mixed results, with sabatolimab plus hypomethylating agents demonstrating numerical but not statistically significant survival benefits.

Exploratory analysis of the phase 3 ADAURA trial reveals plasma-based, tumor-informed minimal residual disease (MRD) detection can predict disease recurrence in resected EGFR-mutated NSCLC, with MRD positivity preceding clinical recurrence by approximately 4.7 months.

Phase III KEYNOTE-921 trial demonstrates that adding pembrolizumab to docetaxel did not significantly improve radiographic progression-free survival or overall survival in previously treated metastatic castration-resistant prostate cancer patients.

• PSMA PET imaging has revolutionized prostate cancer diagnosis and treatment monitoring from early to advanced stages, marking a significant advancement in precision medicine. • The FDA approval of Pluvicto (lutetium Lu 177 vipovotide tetraxetan) represents a breakthrough in targeted therapy for PSMA-positive metastatic castration-resistant prostate cancer patients. • Emerging targeted treatments, including antibody-drug conjugates and bispecific antibodies, are expanding therapeutic options beyond traditional androgen-targeted and chemotherapy approaches.

A groundbreaking Phase 1 trial at Yale Cancer Center demonstrated successful anti-cancer immune responses in all nine patients with advanced kidney cancer using personalized therapeutic vaccines.

• Current FDA-approved immunohistochemistry (IHC) tests for breast cancer show significant concordance issues, with rates varying from 25% to 80%, highlighting urgent need for more accurate testing methods. • Dr. David Rimm and his team at Yale are developing quantitative fluorescence technology that could provide precise molecular measurements in attomoles per square mm, similar to blood-based testing accuracy. • The shift from subjective pathologist readings to automated, quantitative measurements using AI and digital technologies promises to bridge the accuracy gap in breast cancer diagnostics.